Table IV.
Cumulative effect of unfavorable genotypes in stage III patients receiving 5-FU-based adjuvant chemotherapya
| No. of unfavorable genotypes | No. event/Event | HRb (95% CI) | P value | Log-rank P |
| Recurrence | ||||
| Low risk (0) | 50/12 | 1 (reference) | ||
| Medium risk (1) | 59/19 | 2.33 (0.97–5.62) | 0.059 | |
| High risk (2) | 19/10 | 4.67 (1.60–13.64) | 0.005 | 0.237 |
| Trend | 0.004 | |||
| Survival | ||||
| Low risk (0) | 26/1 | 1 (reference) | ||
| Medium risk (1) | 81/10 | 1.69 (0.19–14.97) | 0.640 | |
| High risk (2–3) | 36/15 | 9.84 (1.23–78.65) | 0.031 | 0.0013 |
| Trend | 0.0006 |
a
Unfavorable genotypes: rs10749971 (AA) and rs961253 (CC) for recurrence; rs961253 (CC), rs4464148 (GG) and rs6983267 (CA + AA) for survival.
b
HR adjusted by age, gender, race, tumor location and histology grade.